Cellect. On track with its strategic plans; ApoGraft POC final results estimated to be published by mid-2019; sufficient cash to support clinical and preclinical trials; target price unchanged. Read More » Cellect. On track with its strategic plans; successfully completed proof of concept for ApoTainerTM; sufficient cash to support clinical and preclinical trials; price target unchanged Read More » Cellect Biotechnology Ltd.: Significant recently reported findings open the ApoGraft™ platform to also be used in the fat-derived stem cell segment; price target raised to $16.9 Read More » Cellect Biotechnology Ltd.: Company’s clinical development on track; we expect positive interim results in the coming months. Target Price unchanged. Read More » Cellect Biotechnology Ltd.: Exposure to the global stem cells industry Read More »
Cellect. On track with its strategic plans; ApoGraft POC final results estimated to be published by mid-2019; sufficient cash to support clinical and preclinical trials; target price unchanged. Read More »
Cellect. On track with its strategic plans; successfully completed proof of concept for ApoTainerTM; sufficient cash to support clinical and preclinical trials; price target unchanged Read More »
Cellect Biotechnology Ltd.: Significant recently reported findings open the ApoGraft™ platform to also be used in the fat-derived stem cell segment; price target raised to $16.9 Read More »
Cellect Biotechnology Ltd.: Company’s clinical development on track; we expect positive interim results in the coming months. Target Price unchanged. Read More »
